Every 8-K that Stereotaxis, Inc. (STXS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow STXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STXS filings page.
Stereotaxis, Inc. reported 2026 second quarter results with total revenue of $7.7 million for the quarter ended June 30, 2026, compared with $8.8 million a year earlier. System revenue was $1.5 million, down from $3.0 million in the prior-year quarter, reflecting the absence of a robotic system delivery, partially offset by initial Synchrony digital operating room sales. Recurring revenue from disposables, service, and accessories was $6.2 million, up from $5.8 million, supported by new robotic catheter contributions.
Gross margin was 58% of revenue. Operating expenses were $9.1 million, including $2.5 million of non-cash items, resulting in an operating loss of ($4.6) million and a net loss of ($4.5) million, compared with ($3.8) million a year earlier. Cash and cash equivalents were $10.5 million with no debt at June 30, 2026, and negative free cash flow was ($3.7) million.
The company highlighted that robotic catheter revenue surpassed $1 million with 270% sequential growth, reported the first U.S. GenesisX system purchase, multiple Synchrony installations following April FDA clearance, and completion of the Robocath acquisition. Management expects recurring revenue of approximately $7 million in the third quarter and $8 million in the fourth quarter, system revenue of about $3 million in each quarter, and anticipates reaching cash flow profitability in the first half of 2027.
Stereotaxis, Inc. reports that on July 7, 2026 it completed the acquisition of Robocath, obtaining 100% of its share capital and voting power. The company describes extensive integration, operational, regulatory, labor and tax risks as it assumes Robocath’s complex robotic systems and disposable products business.
At closing Stereotaxis issued 6,269,628 common shares, including 225,000 shares to Robocath’s financial advisor, and had extended $1.1 million of operating loans between signing and closing that were repaid and reduced upfront stock consideration. The Share Sale Agreement provides for up to $25 million in milestone-based earnout payments, payable in cash, Earnout Shares or Purchaser Warrants. Stereotaxis elected to register 13,179,975 Earnout Shares, with total Closing and Earnout Shares capped at 19.9% of shares outstanding as of July 7, 2026, creating the potential for significant dilution if milestones are met. Management states the Robocath acquisition will not be accretive initially and will increase operating losses and negatively impact consolidated results in the near term.
Stereotaxis, Inc. completed its acquisition of French vascular robotics company Robocath for approximately $20 million in cash and common stock. As part of the deal, Stereotaxis issued 1,469,485 shares of common stock and pre-funded warrants to purchase 4,575,143 additional shares to Robocath securityholders.
The company also issued 225,000 shares to Robocath’s financial advisor as part of its success fee and may issue further stock or warrants tied to earnout milestones of up to $25.0 million. Any shares issued in connection with the acquisition will not exceed 19.9% of pre-transaction shares outstanding without stockholder approval. Stereotaxis plans to file a resale registration statement covering the stock consideration and an estimate of earnout-related shares.
Stereotaxis, Inc. reported the results of its May 14, 2026 Annual Meeting of Shareholders. A total of 97,477,538 common shares were entitled to vote, and Series A Convertible Preferred Stock carried 23,705,445 votes on an as-converted basis, for 121,182,983 total voting power. Quorum was achieved with 79,183,920 votes represented, about 65.34% of voting power.
Shareholders elected three Class I directors to serve until the 2029 annual meeting. David Benfer, Arun Menawat, and Myriam Curet each received between 49,544,105 and 52,711,903 votes for, with relatively low opposition. Shareholders also ratified Ernst & Young LLP as independent auditor for fiscal 2026 by 79,036,638 votes for versus 112,633 against and approved, on a non-binding basis, executive compensation with 52,143,334 votes for and 985,434 against.
Stereotaxis, Inc. reported first quarter 2026 results alongside major strategic and regulatory milestones. Revenue was $6.3 million, down from $7.5 million in the prior-year quarter, with systems revenue of $1.3 million and recurring revenue of $5.0 million.
Gross margin was 60%, and the company posted an operating loss of $6.0 million and net loss of $5.9 million. Adjusted operating expenses were $6.7 million, roughly flat versus the prior year, and negative free cash flow was $3.5 million. Stereotaxis ended March 31, 2026 with $14.6 million in cash and no debt.
The company highlighted U.S. FDA approval of its MAGiC robotically-navigated catheter in January and Synchrony digital operating room system in April, both now in commercial use. It also signed a definitive agreement to acquire Robocath, expanding its robotic platform. Stereotaxis expects double-digit revenue growth in 2026, total revenue above $40 million, and third- and fourth-quarter revenue each above $10 million, supported by manufacturing ramps for GenesisX and MAGiC.
Stereotaxis, Inc. agreed to acquire 100% of French robotics company Robocath through a Share Sale Agreement. The company will deliver initial consideration valued at $20.0 million in cash, Stereotaxis common stock based on $2.00 per share, or a mix, subject to closing adjustments.
The sellers may also receive up to $25 million in earnout payments tied to one FDA regulatory milestone and two commercial sales milestones. Part of the stock consideration may instead be delivered as pre-funded warrants, and total stock issued for upfront and milestone consideration is capped at 19.9% of shares outstanding before closing under NYSE American rules.
Stereotaxis will provide Robocath interim financing via monthly bonds initially expected to total about €1,300,000. Closing is targeted for July 2026, subject to debt restructuring, French regulatory clearance, absence of blocking legal orders or material adverse effects, and other customary conditions, with an outside end date of December 31, 2026.
Stereotaxis, Inc. reported strong growth for 2025, with revenue rising to $32.4 million, up from $26.9 million, driven by new robotic systems and recurring disposables and service revenue. Fourth-quarter revenue reached $8.6 million, a 36% increase year over year.
Full-year gross margin was 53%, and adjusted operating loss improved to ($9.3) million from ($12.4) million. The company ended 2025 with $13.4 million in cash and no debt. Management highlighted regulatory approvals and initial commercialization of the GenesisX robot and MAGiC catheter portfolio, while acknowledging manufacturing ramp challenges.
For 2026, Stereotaxis expects double-digit revenue growth, with annual revenue projected to surpass $40 million and lower cash use. The company is targeting higher manufacturing volumes, at least five active GenesisX programs, over $3 million of Synchrony digital suite revenue, and progress across its endovascular robotics and AI-enabled digital solutions.
Stereotaxis, Inc. furnished its third‑quarter 2025 financial results via a press release attached as Exhibit 99.1 to an 8‑K. The company noted that statements in the release may include forward‑looking statements subject to risks and uncertainties. Under General Instruction B.2, the information in Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and will be incorporated by reference only if expressly cited in future filings.
Stereotaxis, Inc. entered into a Sales Agreement with Roth Capital Partners that allows the company to sell shares of its common stock with an aggregate sales price of up to $50,000,000 through at-the-market offerings or privately negotiated transactions. These potential sales are covered by an existing Form S-3 shelf registration that permits up to $100,000,000 of securities, with a new prospectus supplement dated August 29, 2025.
Roth Capital will act as sales agent and/or principal and earn a placement fee of up to 3.0% of the gross sales price of any shares sold, plus specified expense reimbursements. Stereotaxis plans to use any net proceeds for working capital, research and development, and other general corporate purposes, including accelerated commercialization of its innovation pipeline. The company is not obligated to sell any shares, and the program can be suspended or terminated by either party under the agreement’s terms.